Zai Lab Limited (09688.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−12.6x

Market Cap

HKD 22.99B

MomentumView details →

1D Return

−1.42%

YTD Return

+52.09%

RSI (14)

61.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−12.6x

Market Cap

HKD 22.99B

RSI (14)

61.6

MomentumView details →

1D Return

−1.42%

YTD Return

+52.09%

ProfitabilityView details →

Gross Margin

56.47%

Net Margin

−41.86%

EBITDA Margin

−45.43%

ROE (TTM)

−30.97%

ROA (TTM)

−17.49%

Asset Turnover

0.41x

GrowthView details →

Revenue YoY

+5.00%

EPS YoY

+70.44%

FCF YoY

+41.67%

Revenue CAGR 3Y

+28.93%

EPS CAGR 3Y

+38.46%

EBITDA YoY

−4.48%

EarningsView details →

EPS (Actual)

−HKD 0.39

EPS Surprise

28.05%

Beats (12Q)

2/12

Next Q EPS Est

−HKD 0.43

Avg Surprise (4Q)

20.72%

Rev Surprise

2.77%

Capital & dividendView details →

Debt/Equity

0.42x

Current Ratio

2.13x

Quick Ratio

1.92x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

449.20M

Net Income (TTM)

−188.02M

Op. CF (TTM)

−127.33M

Next earningsNov 10, 2026 →

Latest newsMore news →

Zai Lab announced that its DLL3-targeting antibody-drug conjugate zociluratug pelitecan (zoci) has advanced from an Investigational New Drug application to global Phase 3 development in under two years, with the DLLEVATE study evaluating it in second-line and later extensive-stage small cell lung cancer.26d ago

Zai Lab Limited announced its financial results for the second quarter of 2026, along with recent product highlights and corporate updates.30d ago

Similar companies

天坛生物600161.SH Keymed Biosciences Inc.02162.HK Biocytogen Pharmaceuticals (Beijing) Co., Ltd.02315.HK 特宝生物688278.SH Roivant Sciences Ltd.ROIV United Therapeutics CorporationUTHR Find similar companies →

Latest newsMore news →

Zai Lab announced that its DLL3-targeting antibody-drug conjugate zociluratug pelitecan (zoci) has advanced from an Investigational New Drug application to global Phase 3 development in under two years, with the DLLEVATE study evaluating it in second-line and later extensive-stage small cell lung cancer.26d ago Zai Lab Limited announced its financial results for the second quarter of 2026, along with recent product highlights and corporate updates.30d ago The U.S. FDA granted Orphan Drug Designation to Zai Lab's DLL3-targeting ADC zocilurtatug pelitecan for the treatment of neuroendocrine carcinomas.32d ago